RxDoctor Payments Data

Halie Leiker, APRN

Family · Hutchinson, KSNPI 1336771716

Payments from drug & device makers

$3,379in general payments, 2019–2025

Across 107 payments — averaging $31.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$968
  • Boston Scientific$589
  • Sanofi$176
  • Medtronic$163
  • E.r. Squibb & Sons, L.L.C.$125
  • United Therapeutics Corporation$117
  • plus $1K from 22 others

What the payments were for

  • Travel & lodging$94828%
  • Food & beverage$2,39071%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,379 in reported general payments places this provider in the 90th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$82,870
Medicare patients
742
Services billed
1,520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$142,437
XareltoRivaroxaban99$122,593
EntrestoSacubitril/Valsartan37$40,570
JardianceEmpagliflozin16$26,644
Repatha SureclickEvolocumab35$25,720
FarxigaDapagliflozin Propanediol21$18,569
BrilintaTicagrelor16$11,502
Praluent PenAlirocumab19$11,036
Metoprolol Succinate269$2,347
Atorvastatin Calcium346$2,173
ClopidogrelClopidogrel Bisulfate181$1,645
Amiodarone Hcl96$1,421
Diltiazem 24hr Er (Cd)Diltiazem Hcl26$1,108
Midodrine Hcl13$1,056
Ezetimibe60$1,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$142,437152 claims
Johnson & JohnsonXarelto$86$122,59399 claims
NovartisEntresto$52$40,57037 claims
AstraZenecaFarxiga, Brilinta$100$30,07137 claims
Boehringer IngelheimJardiance$41$26,64416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,579 family providers in Kansas.

Other family in Hutchinson

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →